www.aidsmap.com

www.aidsmap.com
Share

www.aidsmap.com

 •  February 14

Most people with hepatitis C virus (HCV) in the GECCO German hepatitis C cohort who were treated with sofosbuvir/ledipasvir (Harvoni) for 8 weeks in a real-world clinical setting achieved sustained virological response, even those who are advised to stay on treatment for 12 weeks due to factors such as liver cirrhosis, prior treatment experience or...

www.aidsmap.com

 •  February 14

The World Health Organization will issue new HIV treatment guidelines later this year recommending treatment for all, regardless of CD4 cell count, Dr Meg Doherty of the WHO Department of HIV/AIDS told a satellite meeting ahead of the 8th International AIDS Society Conference (IAS 2015) in Vancouver on Sunday. The new recommendation follows results...

www.aidsmap.com

 •  February 14

A major international randomised clinical trial has found that people living with HIV have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral treatment (ART) sooner, when their CD4 cell count is above 500 cells/mm3, instead of waiting until their CD4 cell count drops below 350...